Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

13 trials with published results (46%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 28 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

46%

13 trials in Phase 3/4

Results Transparency

62%

13 of 21 completed with results

Key Signals

13 with results100% success

Data Visualizations

Phase Distribution

21Total
P 2 (8)
P 3 (12)
P 4 (1)

Trial Status

Completed21
Unknown5
Recruiting1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (28)

Showing 20 of 20 trials
NCT06672978Phase 2RecruitingPrimary

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

NCT05905055Phase 3Completed

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

NCT06059846Phase 3Completed

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT05887908Phase 3Completed

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

NCT04979806Phase 3Completed

Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT03840148Phase 3Completed

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

NCT04882085Phase 4Completed

Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

NCT04682834Unknown

Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection

NCT06141395Completed

NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification

NCT04654507Phase 3Unknown

Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children

NCT03630081Phase 3Not Yet Recruiting

Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT05674032UnknownPrimary

Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis

NCT04686318CompletedPrimary

Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis

NCT04667195CompletedPrimary

Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis

NCT03788967Phase 3Completed

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT05060419Phase 2Unknown

Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections

NCT02034851CompletedPrimary

Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection

NCT03757234Phase 2CompletedPrimary

IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis

NCT03445195Phase 2Completed

Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections

NCT03477422Phase 3Completed

CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria

Scroll to load more

Research Network

Activity Timeline